Skip to content

Clinical trial of the safety and efficacy of amlodipine Benazepril tablets (II) for antihypertensive treatment in patients with grade 2 hypertension who are not eligible for free association

Clinical trial of the safety and efficacy of amlodipine Benazepril tablets (II) for antihypertensive treatment in patients with grade 2 hypertension who are not eligible for free association

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106011
Enrollment
Unknown
Registered
2025-07-15
Start date
2024-01-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Amlodipine benazepril tablets (?) treatment group:Amlodipine Benazepril tablets (II) (containing amlodipine besylate 5mg and benazepril 10mg) were given as a fixed compound, one tablet a day for 6 wee

Sponsors

Zigong Fourth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age>=18 years and 140/90mm Hg) after treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with type I or type II diabetes; 2. Stroke, myocardial infarction or cerebrovascular event in the past 6 months; 3. Patients who are taking more than three antihypertensive drugs or single tablet combination preparations; 4. Patients with unstable angina; 5. Patients with chronic heart failure; 6. Patients with acute coronary syndrome; 7. Patients with hepatocellular or renal failure; 8. Those who are contraindicated to the use of amlodipine or benazepril; 9. Patients who are taking other medications that may affect blood pressure.

Design outcomes

Primary

MeasureTime frame
The patients' blood pressure reached the standard rate;

Secondary

MeasureTime frame
Changes in mean seated systolic and diastolic blood pressure (SBP/DBP) from baseline;Safety check (blood, urine routine, blood biochemistry, liver function and kidney function, etc.);

Countries

China

Contacts

Public ContactLuo Yu

Zigong Fourth People’s Hospital

wangyily1839@126.com+86 137 6452 2756

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026